AIM VACCINE (06660) saw its shares rise nearly 8% during the trading session. As of the time of writing, the stock was up 6.78%, trading at HK$3.15, with a turnover of HK$2.38 million.

The increase follows the company's recent announcement that on March 30, it passed a resolution to issue no more than 40 million additional domestic shares. This represents approximately 3.26% of the total shares issued prior to the offering and about 3.16% of the total shares after the offering.

Additionally, the company plans to apply for an A-share listing on the Beijing Stock Exchange. According to relevant regulations, the company's domestic shares must first be listed on the National Equities Exchange and Quotations system.

If the process proceeds smoothly, AIM VACCINE is expected to become the first company to transition from a Hong Kong listing to a Beijing Stock Exchange listing, setting a precedent for other biopharmaceutical firms listed in Hong Kong.

Data shows that CanSino Biologics, another vaccine company, has seen its A-share valuation premium over H-shares reach as high as 3.1 times. If AIM VACCINE successfully implements its "H+A" dual-listing strategy, it is expected to not only boost its Hong Kong stock valuation and secondary market liquidity but also significantly enhance its brand value and business development.